Related Experiment Video

Updated: Mar 26, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.5K

Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection: a propensity

Toshifumi Tada1, Takashi Kumada1, Hidenori Toyoda1

  • 1Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Gifu, Japan.

Liver International : Official Journal of the International Association for the Study of the Liver
|January 21, 2016
PubMed

Insights

Hepatitis C virus (HCV) eradication through interferon-based therapy significantly reduces non-liver-related mortality and hepatocellular carcinoma incidence in patients with chronic HCV. This finding highlights the broad health benefits of successful HCV treatment.

Area of Science:

  • Hepatology
  • Virology
  • Public Health

Background:

  • Chronic hepatitis C virus (HCV) infection is a significant global health concern.
  • Interferon (IFN)-based therapy can eradicate HCV, leading to sustained virological response (SVR).
  • While HCV eradication's impact on liver-related mortality is known, its effect on non-liver-related causes of death requires further investigation.

Purpose of the Study:

  • To investigate the impact of HCV eradication on non-liver-related mortality in patients with chronic HCV infection.
  • To analyze the causes of death and incidence of hepatocellular carcinoma (HCC) following HCV eradication.
  • To compare mortality rates between patients achieving SVR, those not achieving SVR, and those not receiving IFN therapy.

Main Methods:

  • A cohort study involving 2743 patients with chronic HCV infection.
  • Patients were categorized into three groups: IFN-SVR (HCV eradication), IFN-non-SVR (no eradication), and non-IFN (no therapy).
  • Propensity score matching was used to create a comparable cohort (Cohort 2) for analysis of mortality and HCC incidence over a median follow-up of 11.4 years.

Main Results:

  • HCV eradication (IFN-SVR) was associated with a significant reduction in all-cause mortality (HR: 0.265) and non-liver-related mortality (HR: 0.439).
  • The incidence of HCC was also significantly reduced in patients who achieved SVR (HR: 0.275).
  • Mortality rates from non-liver-related diseases were substantially higher in IFN-SVR patients compared to IFN-non-SVR and non-IFN groups in Cohort 1, but the matched analysis in Cohort 2 confirmed the benefit of SVR.

Conclusions:

  • Eradication of HCV through IFN-based therapy significantly reduces not only liver-related mortality but also non-liver-related mortality.
  • Successful HCV treatment offers broader survival benefits beyond preventing liver disease progression.
  • These findings underscore the importance of HCV eradication strategies for improving overall patient outcomes.
Abstract

Keywords:
causes of deatheradication of HCVhepatitis Cnon-liver-related mortalitysurvival

More Related Videos

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.4K
Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection04:11

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

5.1K

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.5K
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
34
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
17
Viruses with RNA Genomes01:29

Viruses with RNA Genomes

RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
1.3K
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
19
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
333